erlotinib hydrochloride has been researched along with Infections in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H | 1 |
Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
2 trial(s) available for erlotinib hydrochloride and Infections
Article | Year |
---|---|
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting | 2012 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |